Getting a proper diagnosis of angioimmunoblastic T-cell lymphoma that has not responded to treatment or has come back is a complex process that involves several different tests and examinations. Understanding these diagnostic steps can help patients feel more prepared and less anxious about what lies ahead.
Introduction: When to Seek Diagnostics
Patients who have been diagnosed with angioimmunoblastic T-cell lymphoma, or AITL, and have undergone treatment should remain vigilant for signs that the disease may not be responding as hoped or has returned. The terms “refractory” and “relapsed” describe two different but equally challenging situations. Refractory disease means the lymphoma did not respond to the initial treatment, with cancer cells continuing to grow despite therapy. Relapsed disease means the lymphoma disappeared for a time but has now come back after a period when the patient felt better, known as remission.[4][6]
Anyone who previously received treatment for AITL should seek immediate medical attention if they notice certain warning signs returning. These include swollen lymph nodes that feel like painless lumps in the neck, armpit, or groin areas. Many people also experience what doctors call B symptoms, which include drenching night sweats, unexplained fevers that come and go, and significant weight loss without trying.[1][3]
Other concerning symptoms that warrant prompt evaluation include extreme tiredness that doesn’t improve with rest, new skin rashes or changes to existing ones, and recurring infections that suggest the immune system isn’t working properly. Some patients notice their abdomen feels bloated or uncomfortable, which can happen when the liver or spleen becomes enlarged.[1][5]
Classic Diagnostic Methods
Tissue Biopsy: The Gold Standard
The most important diagnostic test for confirming refractory or relapsed AITL is a biopsy, which involves removing a sample of tissue so that a specialist can examine it under a microscope. In most cases, doctors remove all or part of a swollen lymph node, a procedure known as an excisional biopsy. This provides the pathologist with enough tissue to make an accurate diagnosis and understand the characteristics of the lymphoma cells.[1][3]
When examining the biopsy sample, the pathologist looks at the appearance and behavior of the cells. For AITL, they check whether abnormal T lymphocytes are present and look for specific markers on the cell surface. In refractory or relapsed cases, doctors may compare the new biopsy results with the original diagnostic sample to see if the lymphoma has changed. Sometimes cancer cells develop new characteristics or lose certain features they had before, which can affect treatment decisions.[1][2]
The biopsy also allows doctors to perform molecular tests, including checking for clonal T-cell receptor rearrangement. This test uses a technique called polymerase chain reaction, or PCR, to confirm that the T cells are all abnormal copies of a single cell, which is the hallmark of lymphoma. When disease relapses, doctors can compare the genetic fingerprint of the new lymphoma cells with the original ones to confirm it’s the same disease returning rather than a new cancer.[5][7]
Blood Tests
Blood tests play multiple important roles in diagnosing and monitoring refractory or relapsed AITL. A complete blood count checks for low levels of red blood cells, white blood cells, and platelets. When lymphoma cells grow in the bone marrow, they can crowd out normal blood cells, leading to anemia (low red blood cells), which causes tiredness and shortness of breath. Low platelet counts, called thrombocytopenia, can lead to easy bruising and bleeding.[3][5][7]
Additional blood tests measure levels of certain proteins that give doctors clues about disease activity. Lactate dehydrogenase, or LDH, is an enzyme that often becomes elevated when cells are breaking down rapidly, as happens in aggressive lymphomas. High LDH levels generally indicate more active disease. Other blood tests check liver and kidney function, which helps doctors understand if lymphoma has affected these organs or if previous treatments have caused any damage.[1][5][7]
Some patients with AITL develop autoimmune disorders, where the immune system mistakenly attacks the body’s own healthy tissues. Blood tests can detect signs of autoimmune hemolytic anemia, where the immune system destroys red blood cells, by performing a test called a Coombs test. They can also identify immune thrombocytopenia, where platelets are destroyed. These conditions are characteristic features of AITL and their presence or worsening can signal active disease.[1][5][7]
Bone Marrow Biopsy
A bone marrow biopsy involves removing a small sample of the soft, spongy tissue inside certain bones, usually from the hip bone. This test determines whether lymphoma cells have spread to or grown in the bone marrow. During the procedure, doctors first numb the area, then use a special needle to withdraw a tiny piece of bone marrow. The sample goes to a laboratory where specialists examine it under a microscope to look for abnormal lymphoma cells among the normal blood-forming cells.[1][3]
Bone marrow involvement is important information because it affects how doctors classify the stage of disease and influences treatment planning. When lymphoma cells are found in the bone marrow, it typically means the disease is more widespread. In one detailed case example, bone marrow examination showed that five percent of the marrow was involved by AITL, which helped doctors understand the full extent of the patient’s disease.[5][7]
Imaging Studies
Several types of imaging tests help doctors see where lymphoma is located in the body and how much disease is present. A computed tomography scan, or CT scan, uses X-rays taken from many angles and combines them with computer processing to create detailed cross-sectional images of the body. CT scans can reveal enlarged lymph nodes in areas that can’t be felt during a physical examination, such as deep in the chest or abdomen.[1][3]
A positron emission tomography scan, called a PET scan, works differently from a CT scan. Before the test, patients receive an injection of a small amount of radioactive sugar. Cancer cells, which grow quickly and use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan. PET scans are particularly useful for distinguishing between scar tissue from previous treatment and active lymphoma that may be growing.[1][5][7]
Often doctors combine these two technologies in what’s called a PET-CT scan, which provides both the metabolic information from the PET scan and the detailed anatomical pictures from the CT scan in a single test. This combined approach gives the most complete picture of disease location and activity. In one documented case, a PET scan revealed hypermetabolic lymphadenopathy, which means metabolically active enlarged lymph nodes, in multiple body regions including the neck, armpit, abdomen, and pelvis, along with splenomegaly and fluid around the lungs.[3][5][7]
Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues in the body. While not always necessary for AITL diagnosis, MRI can be helpful in certain situations, such as when doctors need to examine the brain, spinal cord, or other areas where detailed soft tissue imaging is important.[1]
Disease Staging
After completing all diagnostic tests, doctors determine the stage of the lymphoma, which describes how much of the body is affected and where the disease is located. There are four main stages, numbered with Roman numerals from I to IV. Stage I means lymphoma is found in only one lymph node area or one organ. Stage II indicates disease in two or more lymph node regions on the same side of the diaphragm, the muscle that separates the chest from the abdomen.[1][3]
Stage III means affected lymph nodes are found both above and below the diaphragm. Stage IV, the most advanced stage, indicates that lymphoma has spread to one or more organs beyond the lymph nodes, such as the bone marrow, liver, lungs, or skin. Most patients with AITL have advanced disease at diagnosis, meaning Stage III or IV, and this pattern often continues when disease relapses. Early stage disease, Stage I or II, is quite rare in AITL.[1][3]
Diagnostics for Clinical Trial Qualification
Standard Eligibility Criteria
Clinical trials testing new treatments for relapsed or refractory AITL have specific requirements that patients must meet to participate. These requirements, called eligibility criteria, help ensure patient safety and that study results are reliable. Most trials require confirmed diagnosis through biopsy showing that the lymphoma truly is AITL or a closely related subtype. The biopsy must demonstrate that the disease either never responded to initial treatment or has returned after a period of remission.[4][6]
Trials typically specify that patients must have received at least one prior line of chemotherapy. Some studies accept patients who have had only first-line treatment, while others may require patients to have tried and failed multiple different regimens. Documentation of all previous treatments, including dates, drug names, and whether the lymphoma responded, is essential for trial enrollment.[10]
Performance Status Assessment
An important criterion for most clinical trials is the patient’s performance status, which measures how well someone can take care of themselves and perform daily activities. The most common scale used is the Eastern Cooperative Oncology Group, or ECOG, performance status scale, which ranges from 0 to 5. A score of 0 means the person is fully active and able to do everything they did before getting sick. A score of 1 indicates some restrictions on physically strenuous activity but ability to do light work. Higher scores indicate more limitation.[1]
Most clinical trials require patients to have an ECOG performance status of 0, 1, or sometimes 2, meaning they can walk around and take care of their basic needs even if they can’t work or do heavy activities. This requirement exists because patients need to be strong enough to tolerate experimental treatments and complete the study procedures. The ECOG score is also a factor in the AITL Score, a prognostic tool that helps predict outcomes in AITL patients.[1]
Laboratory Parameters
Clinical trials establish specific laboratory values that patients must meet to enroll safely. Blood tests must show that the bone marrow is producing enough blood cells, typically requiring certain minimum levels of white blood cells, red blood cells, and platelets. These requirements ensure patients can tolerate chemotherapy or other treatments without experiencing dangerous drops in blood counts.[10]
Liver and kidney function tests must fall within acceptable ranges because most drugs are processed through these organs. If the liver or kidneys aren’t working well enough, medications could build up to dangerous levels in the body. Specific tests include measurements of liver enzymes, bilirubin (a breakdown product processed by the liver), and creatinine (which reflects kidney function).[10]
Prognostic Scoring Systems
Some clinical trials use prognostic scoring systems to categorize patients by risk level. The AITL Score is a recently developed tool specifically designed for angioimmunoblastic T-cell lymphoma. This score divides patients into low-risk, intermediate-risk, and high-risk categories based on four factors: age, ECOG performance status, level of C-reactive protein (CRP, a protein the liver makes in response to inflammation or tissue damage), and level of β2 microglobulin (a protein that increases in some cancers including lymphoma).[1]
Understanding a patient’s risk category helps researchers design better trials and helps doctors predict how someone might respond to treatment. Clinical trials may specifically enroll patients from certain risk categories or use risk stratification to balance the groups receiving different treatments.[1]
Measurable Disease Requirements
Most clinical trials require that patients have measurable disease, meaning lymphoma that can be seen and measured on imaging scans. This allows researchers to determine whether the experimental treatment is working by comparing scans taken before and during treatment. Measurable disease is typically defined as at least one lymph node or tumor mass that measures a certain minimum size, often at least 1.5 centimeters in one dimension.[10]
Imaging studies performed as part of trial screening must be recent, usually done within a few weeks before starting the study treatment. This ensures that the pictures accurately reflect the current state of disease. Both PET and CT scans may be required at baseline to establish starting measurements.[10]
Additional Testing for Specific Trials
Depending on the type of treatment being studied, clinical trials may require additional specialized tests. Trials testing drugs that target specific genetic mutations might require genetic testing of the lymphoma cells to confirm the target is present. Studies evaluating treatments that affect the heart might require an electrocardiogram (EKG) or echocardiogram to ensure the heart is healthy enough for the treatment.[10]
Some newer trials test combinations of drugs that work through different mechanisms. For instance, one study evaluated a combination of rituximab, lenalidomide, and chidamide for relapsed or refractory AITL. While the specific diagnostic requirements weren’t detailed in all cases, such trials typically require comprehensive baseline testing to monitor for side effects and measure treatment response.[10]
